Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
Tesla: The Thesis Is Stronger Than Ever
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
EBS Stock News and Mentions of Emergent BioSolutions Inc. Stocktwits
Updated: May 2, 2024 (01:57)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Emergent BioSolutions Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Emergent BioSolutions Inc. (EBS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Emergent BioSolutions stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Emergent BioSolutions Inc. (EBS)
May 2, 2024 (03:45) / "Motley Fool" (by Motley Fool Transcribing)
Emergent BioSolutions ( EBS ) Q1 2024 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
May 1, 2024 (20:57) / "GlobeNewswire" (by Inc.)
Emergent BioSolutions Reports First Quarter 2024 Financial Results
GAITHERSBURG, Md., May 01, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today reported financial results for the first quarter ended March 31, 2024.
In Article Trend: Neutral
May 1, 2024 (20:10) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position - Emergent BioSolutions ( NYSE:EBS )
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently Reorganization will align with evolving business goals, strategic priorities and new operational plan
In Article Trend: Somewhat-Bullish
May 1, 2024 (15:03) / "GlobeNewswire" (by Inc.)
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
GAITHERSBURG, Md., May 01, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college ...
In Article Trend: Neutral
April 30, 2024 (21:26) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Announces Amendment to its Existing Credit Facility - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., April 30, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility.
In Article Trend: Somewhat-Bullish
April 30, 2024 (21:26) / "GlobeNewswire" (by Inc.)
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
GAITHERSBURG, Md., April 30, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) announced that it has entered into a "Consent, Waiver and Seventh Amendment" to its existing credit facility.
In Article Trend: Somewhat-Bullish
April 29, 2024 (14:01) / "Associated Press" (by ADAM BEAM)
California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
SACRAMENTO, Calif. ( AP ) - California is partnering with a New Jersey-based pharmaceutical company to purchase a generic version of Narcan, the drug that can save someone's life during an opioid overdose, under a deal announced Monday by Democratic Gov. Gavin Newsom.
In Article Trend: Somewhat-Bullish
April 25, 2024 (09:48) / "Zacks Commentary" (by Zacks Equity Research)
Strength Seen in Amneal ( AMRX ) : Can Its 12.0% Jump Turn into More Strength?
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
April 22, 2024 (12:05) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., April 22, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, ...
In Article Trend: Somewhat-Bullish
April 22, 2024 (12:05) / "GlobeNewswire" (by Inc.)
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GAITHERSBURG, Md., April 22, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "GlobeNewswire" (by XORTX Therapeutics Inc.)
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (11:30) / "Benzinga" (by Globe Newswire)
XORTX Welcomes New Member to the Board of Directors - Gamida Cell ( NASDAQ:GMDA )
CALGARY, Alberta, April 08, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) XRTXXRTXANUA ) ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:15) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis - Emergent BioSolutions ( NYSE:EBS )
As the first-ever U.S. Food and Drug Administration ( FDA ) approved over-the-counter ( OTC ) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country
In Article Trend: Neutral
March 28, 2024 (12:15) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GAITHERSBURG, Md., March 28, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S.
In Article Trend: Neutral
March 26, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE VALNVLA, a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika ...
In Article Trend: Neutral
March 26, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain ( France ) , March 26, 2024 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the ...
In Article Trend: Neutral
March 25, 2024 (12:05) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md., March 25, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) announced that the U.S. Food and Drug Administration ( FDA ) has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility.
In Article Trend: Somewhat-Bullish
March 25, 2024 (12:05) / "Benzinga" (by Globe Newswire)
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility - Emergent BioSolutions ( NYSE:EBS )
GAITHERSBURG, Md., March 25, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. EBS announced that the U.S. Food and Drug Administration ( FDA ) has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility.
In Article Trend: Somewhat-Bullish
March 20, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Product sales surpassed pre-pandemic ( 2019 ) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022 Cash position of €126.1 million at year-end 2023 enhanced by €95 million from sale of Priority Review Voucher ( PRV ) 1
In Article Trend: Somewhat-Bullish
March 20, 2024 (06:00) / "GlobeNewswire" (by VALNEVA)
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Total revenues of €153.7 million, including product sales of €144.6 million ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:34) / "Zacks Commentary" (by Zacks Equity Research)
Emergent ( EBS ) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
In Article Trend: Neutral
March 7, 2024 (13:05) / "Benzinga" (by Avi Kapoor)
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - ADT ( NYSE:ADT ) , AudioEye ( NASDAQ:AEYE )
Shares of Rush Street Interactive, Inc. RSI rose sharply in today's pre-market trading as the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for 2024.
In Article Trend: Somewhat-Bullish
March 7, 2024 (04:30) / "Motley Fool" (by Motley Fool Transcribing)
Emergent BioSolutions ( EBS ) Q4 2023 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 6, 2024 (22:55) / "Zacks Commentary" (by Zacks Equity Research)
Emergent Biosolutions ( EBS ) Reports Q4 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -133.33% and 11.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 6, 2024 (22:02) / "Benzinga" (by Erica Kollmann)
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement - Emergent BioSolutions ( NYSE:EBS )
Emergent Biosolutions Inc EBS shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:31) / "GlobeNewswire" (by Emergent Biosolutions)
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GAITHERSBURG, Md., March 06, 2024 ( GLOBE NEWSWIRE ) -- Emergent BioSolutions Inc. ( NYSE: EBS ) today reported financial results for the quarter and year ended December 31, 2023.
In Article Trend: Neutral
Related stocks from Healthcare sector
Deciphera Pharmaceuticals, Inc. (DCPH)
Pasithea Therapeutics Corp. (KTTA)
Kura Oncology, Inc. (KURA)
Altamira Therapeutics Ltd. (CYTO)
BioXcel Therapeutics, Inc. (BTAI)
Cardinal Health, Inc. (CAH)
Mind Medicine (MindMed) Inc. (MNMD)
Organon & Co. (OGN)
Walgreens Boots Alliance, Inc. (WBA)
Antares Pharma, Inc. (ATRS)
This website uses cookies to ensure you get the best experience on our website